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Growth hormone deficiency (GHD) results in an impaired health-related quality of life
(HrQoL) and cognitive impairment in the attention and memory domain. GHD is assumed
to be a frequent finding after brain injury due to traumatic brain injury (TBI), aneurysmal
subarachnoid hemorrhage (SAH) or ischemic stroke. Hence, we set out to investigate the
effects of growth hormone (GH) replacement therapy in patients with isolated GHD after
brain injury on HrQoL, cognition, and abdominal fat composition. In total, 1,408 patients
with TBI, SAH or ischemic stroke were screened for inclusion. Of those, 54 patients
(age 18–65 years) were eligible, and 51 could be tested for GHD with GHRH-L-arginine.
In 6 patients (12%), GHD was detected. All patients with isolated GHD (n = 4 [8%],
male, mean age ± SD: 49.0 ± 9.8 years) received GH replacement therapy for 6
months at a daily dose of 0.2–0.5mg recombinant GH depending on age. Results were
compared with an untreated control group of patients without hormonal insufficiencies
after brain injury (n = 6, male, mean age ± SD: 49.5 ± 13.6 years). HrQoL as well as
mood and sleep quality assessed by self-rating questionnaires (Beck Depression Index,
Pittsburgh Sleep Quality Index) did not differ between baseline and 6 months within
each group or between the two groups. Similarly, cognitive performance as assessed
by standardized memory and attention tests did not show significant differences within
or between groups. Body mass index was higher in the control vs. the GH replacement
group at baseline (p = 0.038), yet not different at 6 months and within groups.
Visceral-fat-by-total-fat-ratio measurements obtained from magnetic resonance imaging
in 2 patients and 5 control subjects exhibited no consistent pattern. In conclusion,
this single center study revealed a prevalence of GHD of about 12% (8% with isolated
GHD) in brain injury patients which was lower compared with most of the previously
reported cohorts. As a consequence, the sample size was insufficient to conclude on
a benefit or no benefit of GH replacement in patients with isolated GHD after brain
injury. A higher number of patients will be necessary to draw conclusions in future studies.
Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT01397500.
Keywords: growth hormone, brain injury, neurorehabilitation, cognition, health-related quality of life, depression,
visceral fat
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INTRODUCTION
Pituitary insufficiency is assumed to be a frequent finding after
traumatic brain injury (TBI) and subarachnoid hemorrhage
(SAH) (1–4). In a systematic review of 19 studies that included
1,137 patients, the pooled prevalences of hypopituitarism in the
chronic phase after TBI and SAHwere 27.5 and 47%, respectively
(2). Also after ischemic stroke, hypopituitarism is a prevalent
condition. In one study pituitary dysfunction was detected in
37.5% of patients with ischemic stroke (1). Previously we have
shown that neuroendocrine disturbances often persist over years
after TBI or SAH (5) with the highest prevalence being observed
1–2 years post-injury. However, transient deficiency is also a
known phenomenon, and patients may potentially recover from
gonadotropic and somatotropic insufficiency (6).
Among the different disturbances, growth hormone deficiency
(GHD) is the most frequent neuroendocrine abnormality after
TBI and SAH (7). Clinical symptoms of GHD and signs often are
unspecific and similar to the sequelae of brain damage itself and
thus often remain undetected in brain injured patients (8).
In patients with pituitary adenomas, GHD has been shown to
be associated not only with major changes in body composition
such as diminished muscle strength and loss of bone mass, but
also with impaired health-related quality of life (HrQoL) and
cognitive deficits (9, 10). In addition, growth hormone (GH) has
received attention as a possible general treatment directed toward
repair of neural injuries, mainly due to its ability to promote
neurogenesis in response to brain damage (11). Recombinant
injected GH reaches the cerebrospinal fluid in GH deficient
humans (12) from where it likely exerts its direct effects in
the central nervous system. In animal models, treatment with
GH in vitro (11) fosters the proliferation of hippocampal stem
cells, and similarly, administration of IGF-1 in vivo has been
reported to induce neurogenesis in the adult rat hippocampus
(13). Furthermore, a neuroprotective role of GH, at least in part
be mediated by IGF-1, has been suggested (14).
Preliminary evidence indicating that patients may benefit
from GH replacement during neurorehabilitation in terms of
HrQoL and cognition comes from small studies (15–20) and
case reports (21–23). Table 1 summarizes these studies including
the applied definition of GHD, GH dosage for substitution
therapy, follow-up time, and key results. Two recent case reports
suggest that improvements in memory and other cognitive
domains as well as physical functions may even occur in
the absence of pituitary dysfunction (22, 23). GH deficient
patients in neurorehabilitation might therefore benefit from
GH replacement or treatment. However, due to the overlap of
symptoms of brain injury and hormone deficiency, it is not clear
to what extent hormone deficiency actually contributes to the
clinical picture and whether hormone replacement would be
beneficial (24).
The aim of the present clinical phase II study was to
investigate whether stable patients with isolated GHD after
brain injury do benefit from GH replacement therapy during
neurorehabilitation. For this purpose, changes in HrQoL and
cognition as well as of body fat composition following GH
replacement therapy over 6 months in patients after brain injury
due to TBI, SAH, or ischemic stroke were compared with brain
injured patients without pituitary insufficiency.
MATERIALS AND METHODS
Patients
All patients were attending rehabilitation therapy due to a recent
event or repeated in-patient neurorehabilitation in the Schön
Klinik Bad Aibling, Germany, which is a specialized clinical
center for neurology and neurorehabilitation. Stable patients
were screened from January 2012 to March 2015 in all phases
of rehabilitation, i.e., the post-acute or chronic phase after TBI,
aneurysmal SAH or ischemic stroke, excluding those on intensive
care unit. Hormonal assessment was performed at least 1 month
after the event or later. Main inclusion criteria were age 18–65
years, TBI of all grades, aneurysmal SAH of all grades or ischemic
stroke. Before starting GH treatment, other hormonal axes had
to be sufficient or treated sufficiently with a stable substitution
therapy.
Exclusion criteria were pregnancy and lactation period,
woman of childbearing potential not using an adequate method
of birth control, men who are not willing to use an adequate
method of birth control, previous or concomitant medication
with GH, suspected or known hypersensitivity to GH treatment,
substance abuse, any condition which in the opinion of
the investigator makes the patient unsuitable for inclusion,
participation in another clinical trial with an investigational new
drug, planned treatment or changes in established treatment with
any other drug which might significantly influence the GH axis
or cognitive function (e.g., treatment with antidepressants), non-
ability to perform testing, presence of any other condition listed
in the contraindications or warnings in the local Summary of
Product Characteristics of GH, and onset of GHD before brain
injury.
Assumed α = 0.05 and β = 0.2, the necessary sample size
calculated for this pilot study was 8 patients to detect HrQoL
scores before and after GH replacement that are at least 1.3
fold the pooled standard deviation. We aimed to include at
least 9 patients and 9 controls without pituitary insufficiency
considering a drop-out rate of 10%.
All patients enrolled granted their written informed consent to
participate in this pilot study in accordance with the Declaration
of Helsinki. The study was approved by the ethics committee of
the Bavarian Chamber of Physicians.
Study Design and Treatments
This was an open phase II pilot study to investigate the
influence of GH replacement therapy over 6 months on quality
of life, cognition, body mass index (BMI), and abdominal fat
distribution of GH deficient patients in stable, chronic phase after
brain injury (EudraCT No: 2010-020679-21) in comparison with
patients without pituitary insufficiency and no GH replacement
treatment. Patients with isolated GHD received open treatment
with recombinant human GH SC (Genotropin R©, Pfizer Pharma
GmbH). Since GH requirements decrease with age and are higher
in women than in men (25), the following daily doses were
applied: men <45 years; 0.4mg; ≥45 years: 0.2mg; women <45
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years 0.5mg, ≥45 years: 0.3mg. All GH deficient patients started
with the half dose for the first 4 weeks. A follow-up visit was
scheduled at 8 weeks after starting GH replacement therapy.
A third study group not included in this report included male
patients with hypogonadism.
The primary endpoint of the study was to evaluate changes
in quality of life in GH deficient patients before and 6 months
after GH replacement treatment and in comparison to control
patients. Secondary endpoints included changes in cognition
scores, BMI, and abdominal fat distribution within and between
the study groups.
Assessments
Basic medical history included causes and grading of TBI
according to the Glasgow Coma Scale (26) as well as localization
of SAH and its evaluation according to Hunt & Hess (27), the
World Federation of Neurosurgical Societies (27) and Fisher
scales (28).
According to the study protocol, both the insulin tolerance
test (ITT) and the GH releasing hormone (GHRH)-L-arginine
test were allowed to assess for GHD. The primary aim was to use
the ITT as gold standard to stimulate the hypothalamic-pituitary
GH axis. However, due to patient′s preferences and frequent
contraindications such as seizures, diabetes or heart pain in the
medical history of our patient population, all patients were not
tested for GHDwith the ITT but with the GHRH-L-arginine test.
The GHRH-L-arginine test was performed as described before
(29). In short, a GHRH bolus (1 µg/kg) was injected IV, followed
by an infusion of arginine hydrochloride (0.5 g/kg body weight)
over 30min. Blood was drawn 30, 45, 60, 90, and 120min after
injection and the GH peak was determined. GHD was diagnosed
dependent on BMI values (BMI<25 kg/m2: cut-off≤11.5 ng/mL;
BMI ≥25 to <30 kg/m2: cut-off ≤8 ng/mL; BMI ≥30 kg/m2:
cut-off ≤4.2 ng/mL) (30).
Basal hormone levels such as free thyroxine (fT4) for
the thyroid axis (normal range 0.93–1.7 ng/dL [11.97–21.88
pmol/L]), fasting cortisol (normal range 5–25 µg/dL [0.14–0.69
µmol/L]), and testosterone in men (normal: ≥3.5 ng/mL [≥12.1
nmol/L]) were measured in serum for screening. IGF-1 was
measured 8 weeks after start of the therapy to adjust GH dosage
as it is usually performed in the department of endocrinology at
the Max-Planck-Institute of Psychiatry, Munich. All endocrine
tests and blood drawings were performed between 7:45 and
8:15 a.m. after an overnight fast of at least 12 h. Quality of life
and cognition were evaluated by using standardized instruments
described in Table 2. Changes in weight were evaluated by
BMI, and changes in abdominal fat distribution by MRI based
volumetry. In addition, patients were evaluated for tolerability
of GH replacement therapy by assessing adverse events at every
visit.
MRI Based Abdominal Fat Measurements
Abdominal MRI was acquired at baseline and month 6 in all 10
participants using a breath holding T1-sequence (2D fast spoiled
gradient echo, in-plane resolution 512 × 512 points, field-of-
view 44 × 44 cm2, breath hold acquisition with two imaging
slabs of 20 s each, 2 × 25 slices, slice thickness 8mm, slice gap
1mm) on a 1.5 Tesla clinical MR system (General Electrics, Signa
Xcite, Milwaukee, U.S.A.). Anonymized images were transferred
to the ROI tool of BRUKER Paravision 6.0.1. Here, the border
between the visceral and subcutaneous compartment was defined
manually by a spline curve for each slice, for all slices from the
lower boundary of the liver defined as the most superior slice.
To determine the image intensity of the fat compartment, an
intensity histogram of the slice with the highest average intensity
value (which is an indication for containing fat) underwent
histogram analysis that typically shows a bimodal distribution,
with a lower peak round the intensity of inner organs and skeletal
muscles, and a higher intensity representing the fat compartment.
The cut-off intensity for automated segmentation was then set at
2/3 of the position of the second peak. Per slice, the total volume
of fatty tissue was determined (TF; number of voxels >cut-off
intensity), as well as the volume of fatty tissue inside the visceral
ROI (VF) and the VF-by-total-fat ratio (VTFR). The latter VTF
ratio was averaged between slice 7 and the last slice on which VF
was reliably detected by the rater (between slice 38 and 42); the
resulting VTFRglobal was forwarded to quantitative analysis.
Statistical Analysis
All statistical analyses were performed using SPSS statistics
(Version 20.0, Chicago, USA, SPSS Inc.). To prove for
normal distribution the Shapiro-Wilk test was applied, which
is appropriate for small sample sizes. Due to non-normal
distributed data the non-parametric Mann-Whitney-U test was
used to analyse the differences between the treatment and control
group. For comparison of the pre and post values within each
group the Wilcoxon signed-rank test was used. In all tests, an
alpha level of 0.05 was considered statistically significant.
RESULTS
Patient Disposition and Characteristics
In total, 1,408 patients were screened. Of those, 54 patients met
the inclusion criteria. 60% of the screened patients (n = 808)
were older than 65 years old and thus could not participate
in the study. 8% (n = 108) were not able to perform the
neuropsychological test battery because of severe neurological
and cognitive deficits according to the clinical impression.
Eventually, 54 patients were enrolled in the study the first step of
which was to test for GHD.Of the 54 patients included, hormonal
assessment could not performed in 3 patients due to withdrawal
of consent in 2 patients and technical failure in 1 other patient
(Figure 1).
Thus, 51 of 54 patients underwent the GHRH-L-arginine test
for GHD. In 6 of 51 successfully tested patients (12%) GHD was
detected. In 2 of these patients, additional testosterone deficiency
was detected which disqualified them for participation in this
study. 33 of the 51 successfully tested patients (88%) did not
present with any pituitary insufficiency.
All 4 patients with isolated GHD were included into the
study and underwent GH replacement. Their mean age ±
SD was 49.0 ± 9.8 years. One of these patients had TBI, 2
patients had aneurysmal SAH, and 1 patient had ischaemic stroke
(Table 3).The control group consisted of 4 patients with ischemic
Frontiers in Endocrinology | www.frontiersin.org 4 December 2018 | Volume 9 | Article 723
Leonhardt et al. GH Replacement After Brain Injury
TABLE 2 | Standardized assessment of quality of life and cognition.
Evaluation of HrQoL, Sleep, and Depression
12-Item Short Form Health Survey (SF-12) (31) 12-item self-reported health status
EuroQoL (EQ-5D) (32) Self-completion questionnaire on health outcome
Quality of Life after Brain Injury (QoLIBRI) (33, 34) Assessment of health related QoL and disturbing, negative aspects specifically in brain-injured
patients
Beck Depression Inventory (BDI) (35) Common questionnaire to quantify signs of depression
Pittsburgh Sleep Quality Index (PSQI) (36) Assessment of self-reported sleep quality
Evaluation of cognition
Verbal Learning and Memory Test (VLMT) (37) Test for serial learning and learning of listings tested twice with an interval of 30 min
Tests from the psychological TAP 2.3 test battery of attention (38) • Alertness Test for reaction time
• Test of Vigilance for concentration
• Go/NoGo test for the patients’ reaction within a period of 2min, which is the representative
time for decision making
FIGURE 1 | Patient disposition.
stroke, 1 SAH patient, and 1 TBI patient without proven pituitary
insufficiency. Mean age ± SD of the control group was 49.5 ±
13.6 years. All patients included were male.
Changes in Patient-Reported Outcomes
(PROS) and Performance-Based Outcomes
(PERBOS): Health-Related Quality of Life
and Cognition
In the group of GH deficient patients no significant changes
in any of the HrQoL scores assessed were observed after 6
months of GH replacement therapy with respect to baseline
scores (Table 4). The same was true for the group of control
patients without showing significant changes of quality of life
scores, with the only exception of an improved QoLIBRI score
(p = 0.042). In addition, there were no significant differences
in any test when comparing quality of life scores between the
intervention and control groups at either baseline or 6 months
(Table 4).
Concerning the secondary endpoints of changes in the TAP
subtests on Alertness, Go/NoGo and Vigilance as well the VLMT
the results did not differ significantly either with time or between
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TABLE 3 | Baseline characteristics of individual patients.
Lesion Sex Age (years) Time to injury (days) Severity BMI (kg/m2)
GHD GROUP, n = 4
Ischemic infarction Male 51 25 NA 24.5
TBI Male 40 78 Grade III 23.3
SAH Male 62 94 Fischer grade II, WFNS grade I 21.9
SAH Male 43 1,024 Hunt & Hess grade IV; Fischer grade III 25.6
CONTROL GROUP, n = 6
SAH Male 56 63 Hunt & Hess grade III; Fischer grade III 27.2
Ischemic infarction Male 52 53 NA 29.6
Ischemic infarction Male 54 41 NA 26.1
Ischemic infarction Male 56 66 NA 23.4
Ischemic infarction Male 57 2,566 NA 26.7
TBI Male 22 132 Grade III 26.4
GH, growth hormone; NA, not applicable; SAH, subarachnoid hemorrhage; TBI, traumatic brain injury; WFNS, World Federation of Neurosurgical Societies.
TABLE 4 | Changes of quality of life scores in patients with GH replacement therapy and controls.
Test GH replacement Control group P-values
Baseline 6 months Baseline 6 months Group comparisons: baseline vs. 6 mo
(GH/control) Time comparisons: GH vs. control
(baseline/6 mo)
QoL
SF-12
Physical 37.8 ± 11.4
(n = 4)
55.9 ± 1.3
(n = 2)
48.4 ±6.4
(n = 6)
46.3 ± 11.8
(n = 6)
NA/0.144
0.200/NA
Psychological 46.0 ± 9.9
(n = 4)
47.1 ± 15.3
(n = 2)
50.8 ± 8.8
(n = 6)
56.3 ± 8.2
(n = 6)
NA/0.465
0.686/NA
EQ-5D (VAS) 63.8 ± 26.9
(n = 4)
67.0 ± 30.7
(n = 4)
51.3 ± 8.9
(n = 6)
60.7 ± 7.7
(n = 6)
0.273/0.157
0.730/0.556
QoLIBRI 59.8 ± 18.1
(n = 4)
69.3 ± 21.5
(n = 4)
77.9 ± 19.2
(n = 5)
82.6 ± 17.5
(n = 5)
0.068/0.042
0.286/0.413
BDI 13.3 ± 5.0
(n = 4)
11.5 ± 7.0
(n = 4)
9.2 ± 6.8
(n = 5)
5.2 ± 5.0
(n = 5)
0.285/0.109
0.556/0.111
PSQ1 6.5 ± 3.3
(n = 4)
5.0 ± 3.7
(n = 4)
4.0 ± 1.7
(n = 5)
4.8 ± 4.1
(n = 5)
0.357/0.496
0.413/1.000
GH, growth hormone; SF-12, Short Form 12; EQ-5D, EuroQoL-5D; QoLIBRI, Quality of life after brain injury; BDI, Beck Depression Inventory; PSQI, Pittsburgh Sleep Quality Index.
the two groups at the beginning or after the intervention (data
not shown). Some of the patients reported on a subjective well-
being after initiating a GH replacement therapy and asked for
continuing the therapy at the end of the study.
IGF-1 and BMI
In the GH replacement group IGF-1 values increased (mean ±
SD) from 128.8 ± 17.3 ng/mL to 214 ± 39.9 ng/mL proving the
effectiveness of replacement therapy. IGF-1 concentration in the
control group at baseline were 216.7± 51.6 ng/mL.
The BMI did not change significantly in either study group.
In the GH replacement group BMI was 23.8 ± 1.6 kg/m2 at
baseline and 24.7 ± 1.6 kg/m2 at 6 months (p = 0.273). In the
control group it was 26.6 ± 2.0 kg/m2 at baseline and 26.5 ± 3.0
kg/m2 at 6 months (p = 0.753). Baseline BMI was significantly
higher in the control group compared to the GH replacement
group (p = 0.038) but there was no significant difference in BMI
between the 2 study groups at 6 months (0.352).
Visceral-to-Total Abdominal Fat Ratio
Analysis
Baseline and follow-up visceral-fat-by-total-fat-ratio
(VTFRglobal) values were available for 2 GH subjects and 5
control subjects (see Figure 2), with no consistent pattern
emerging. The control group was indifferent between both time
points (p > 0.5), and the 2 GH patients also showed no deviating
pattern (no statistics performed).
Adverse Events
Adverse events were observed in all patients who were on GH
replacement therapy consisting of diarrhea, itching, indurated
thyroid, elevated IGF-1 level, confusion (all five adverse events
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FIGURE 2 | Abdominal fat measurement results. (A) Individual visceral/total fat ratio values of 2 GH and 5 controls at baseline and follow-up. Individual subject
numbers are given. Eventually, no consistent or generalizable pattern emerged. (B) Exemplary axial slice (one of about 35 slices) with highlighted subcutaneous
(upper) and visceral fat (lower) ROIs. Calculation of the fat compartment volumes was based on a semiautomated method requiring the manual definition of the inner
border of the subcutaneous compartment and an absolute segmentation threshold gained from the typical bimodal intensity histogram of the slice with the highest
total amount of fat (see section Materials and Methods for details).
in 1 patient), reddened throat (in 2 patients), as well as increased
appetite and atopic eczema of the lower leg (each in 1 patient).
Except for 1 patient who suffered from diarrhea due to infection
with Clostridium difficile adverse events were not serious. All
adverse events resolved and no serious adverse event was
considered related to GH substitution. There was no death in
either study group.
DISCUSSION
Our study confirms previous evidence that patients with brain
injury due to TBI, SAH or ischemic stroke are at risk of
developing GHD. However, in our study cohort, the prevalence
of GHD was 12% and thus at the lower end of the range of
prevalence when considering previous meta-analyses and large
studies (1, 2, 39, 40). The prevalence of isolated GHD was even
lower with only 8% of our screened patients. In contrast to others,
we could not demonstrate significant improvements in HrQoL,
cognition, and BMI following GH replacement therapy in GH
deficient patients with brain injury.
In the past, posttraumatic hypopituitarism was considered to
be a frequent finding. In a meta-analysis by Schneider et al. the
pooled prevalence of GHD ranged between 7.9 and 36.7% in
adult patients with aneurysmal SAH or TBI (2). Even higher
prevalence rates were reported from the German Database on
Hypopituitarism (n = 1,242). In this structured assessment, the
prevalence of hypopituitarism in the chronic phase of patients
with TBI and SAH by laboratory values, physician diagnoses, and
stimulation tests was 35, 36, and 70%, respectively (5).
In the present, these high prevalence rates are raised to
question. A recent review article by Klose et al. summarized
prevalence of pituitary dysfunction from negligible to up to 70%
in adults (41). In our patients using the GHRH-L-arginine test
and BMI-dependent IGF-1 cut-offs the prevalence of isolated
GHD amounted to 12%. This is in accordance with results
such those of Klose et al. who found GHD in 12% of patients
with moderate and severe TBI in the Danish National Study on
Posttraumatic Hypopituitarism (n = 439 patients), also when
testing with GHRH-L-arginine (42).
However, some endocrinologists require the proof of GHD
using two different GH stimulation tests. Thus, GHD would only
be considered when both tests reveal lowered stimulated GH
values. This has also been investigated in theDanish cohort. GHD
was only confirmed in 1% (and not in 12%) of patients when 2
tests identifying GHD were performed.
Applying both the ITT and the GHRH-L-arginine test in one
patient may dramatically reduce the prevalence of GHD. In our
study, both the ITT and the GHRH-L-arginine test were generally
allowed, but due to the specific clinical profile of our patient
cohort, only the GHRH-L-arginine test was applied; we did not
confirm the presence of isolated GHD with a second stimulation
test. Generally, the mentioned diversity in the prevalence rates
due to different endocrine test assays including reproducibility,
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cut-off selection, assay heterogeneity, pre-test probability of
hypopituitarism, and inappropriate reference population (40),
may lead to two problems:
First, an over-conservative definition of the presence of a
GHD after brain injury may falsely preclude patients from being
enrolled in a GH study, despite a potential clinical benefit,
which generally hampers the progress in answering the efficacy
question. Beyond this, also the pathophysiological processes
during recovery from brain injury with a potentially higher
need of GH put into question, if standard cut-offs to diagnose
isolated GHD are ideal to define the indication for a replacement
treatment in brain injury patients. Possibly, also patients with the
GH system working “at the normal limit” could benefit from GH
replacement to foster neuronal recovery (43) and thus may be
included as separate patient subgroup.
Second, due to the masked clinical presentation of GHD in
brain injury patients, the indication for endocrine tests may
be recognized too late in clinical routine, making prevalence
rates unreliable until tested in large and heterogeneous brain
injury populations with different endocrine tests to backtrack the
effect of specific injury-related risk factors (such as brain injury
location or type) and the endocrine cut-off criteria. Such refined
epidemiological studies including elderly patients are essential to
define the ideal patient population for GH replacement studies.
In regard to the aging population the inclusion of elderly patients
is necessary to reflect clinical settings. First insights suggest that
elderly patients with GHD benefit fromGH replacement showing
improved cognitive function (44). Hence, elderly patients with
GHD after brain damage should not be excluded from clinical
studies investigating the effect of GH replacement on cognition.
It should be taken into account that lower GH dosages are needed
in elderly patients (25).
The best time window for GH treatment after brain injury is
not known. Several studies included patients many years after
brain injury (see Table 1). Devesa et al. reported about patients
even 11 years after TBI. This may be due to the delay in diagnosis
and the confounding symptoms that may occur as sequelae of
brain injury as well as a symptom of GHD. Since GH replacement
is an effective therapy reducing morbidity and mortality in GHD
patients (45, 46), we did not want to exclude patients from
this potentially useful therapy. Therefore, there was no upper
limit for the time between brain injury and GH replacement.
Hence, one of our patients suffered from brain injury even 2.8
years ago. But it can be discussed whether there is an optimal
time window for replacement therapy, especially in regard to
influence neuroplasticity after brain injury. GH is known to
cross the blood-brain barrier (47); and its positive effects on
neuroregeneration have been previously well-described (48). So it
can be assumed that patients after brain injury may benefit from
increasedGH levels in the brain (43). In our study, all participants
screened were in a stable phase after brain injury to avoid that
(i) changes in hormonal levels are only due to acute adjustment
effects and (ii) brain edema hampers GH to permeate through
the blood-brain-barrier. There is no information available on GH
levels in cerebrospinal fluid of our patients. To measure this, a
lumbar puncture would have been necessary which would have
increased the burden for participation in our study.
Moreau et al. (15) reported that patients after TBI showed
improvement in cognition and quality of life after replacement
therapy. The authors emphasize that this may be especially true
for patients with severe disabilities. However, such a subgroup
analysis was not possible due to the low sample size in our
study cohort. Since brain pathology is not always related to the
extent of cognitive deficits, we performedMRI scans and assessed
cognitive functioning with neuropsychological tests.
Some limitations in our study deserve consideration.
Although we screened a very large number of patients, only as
few as 54 (3.8%) patients matched our study protocol and were
willing to undergo GH-specific testing. Currently, GHD is not
screened for in clinical routine; instead, the test was part of the
study protocol and needed the patient‘s explicit consent which
naturally reduces inclusion rates. Additional screening drop-outs
were mainly due to age, but also due to severe cognitive deficits
including aphasia, co-medication, co-morbidities, and refusal to
participate.
For assessing HrQoL, time after brain injury can be crucial
and differed between patients. GH und control group were rather
heterogeneous in regard to diagnosis, age, and time since injury.
However, one cannot be sure that small differences between
groups can be ascribed to GHD.
Our study was designed to detect differences in cognition
in patients after brain injury with GHD. Most of the applied
neuropsychological tests are only validated up to the age of 65.
Therefore, the age of our study participants was restricted to
an upper limit of 65 years. Applying this criterion, as much
as 57% of all screened patients were excluded from our study.
In addition, patients had to be able to participate in a detailed
neuropsychological assessment which not possible for 8% of
the patients aged 18–65 years in neurorehabilitation. Less strict
inclusion criteria would have probably allowed including more
patients in our study. This implicates that patient selection
directly affects the number of those who can potentially benefit
from GH replacement. Moreover, the follow-up period of 6
months may have been too short to detect possible long-term
effects in our cohort.
In contrast to other studies (15–19, 21–23) (Table 1), we could
not show improvements in neither generic HrQoL, cognition nor
body composition after GH replacement therapy in the expected
direction. Ameliorated TBI-specific HrQoL was observed in the
control group without pituitary insufficiency 6 months after
baseline assessment. All mentioned results however have to be
seen under the premise of the very small sample sizes and
therefore reduced statistical power to detect significant and valid
changes.
With regard to tolerability, our results may confirm that
administration of GH is safe in brain injured patients (15, 18,
19). However, these results do also not allow for a definitive
conclusion on the safety of GH replacement therapy in GH
deficient patients after brain injury since all studies were small
and rather heterogeneous in nature.
In conclusion, we have screened a very large number of
patients after brain injury due to TBI, aneurysmal SAH, and
ischemic stroke in real-world clinical practice. GHDwas detected
in 12% of all patients assessed with a stimulation test. In 8% of all
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tested patients, isolated GHDwas diagnosed and study treatment
with GH was initiated. At the end, we cannot confirm nor
disprove a benefit of GH replacement in patients with isolated
GHD after brain injury. However, this study is limited by the very
small number of GH deficient patients that could be subjected to
replacement therapy. Summarized, due to only limited supporting
evidence, patients with GHD after brain damage should–if at all–
only receive GH replacement therapy upon an individual decision.
Larger, well-controlled studies are mandatory, that may also
include placebo treatment, elderly patients, and probably also
patients without measurable GHD.
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